Blood Lipid Disorders in Post-Operative Craniopharyngioma Children and Adolescents and the Improvement with Recombinant Human Growth Hormone Replacement

• Published in: Diabetes, metabolic syndrome and obesity Vol. 16; pp. 3075 - 3084
• Main Authors: Du, Han-Ze, Chen, Kang, Zhang, Li-Yuan, Zhang, Yue-Lun, Wu, Dan-Ning, Guo, Xiao-Yuan, Duan, Lian, Wang, Lin-Jie, Yang, Hong-Bo, Chen, Shi, Pan, Hui, Zhu, Hui-Juan
• Format: Journal Article
• Language: English
• Published: Dove Medical Press Limited 30.09.2023; Dove; Dove Medical Press
• Subjects: Children; craniopharyngioma; dyslipidemias; Health aspects; human growth hormone; hypothalamic obesity; Low density lipoproteins; Medical research; Medicine, Experimental; obesity; Obesity in adolescence; Obesity in children; Original Research; Pediatrics; Pituitary gland tumors; Somatotropin; Type 2 diabetes; China
• ISSN: 1178-7007; 1178-7007
• DOI: 10.2147/DMSO.S425399

Context: The high prevalence of hypothalamic obesity (HO) and dyslipidemia in individuals with craniopharyngioma (CP) following surgery is a cause for increasing concern. However, few studies have explored the lipid profile in pediatric CP patients, with inconsistent findings. In addition, the role of recombinant human growth hormone (rhGH) replacement remains unclear in these patients. Objective: To compare the blood lipid profile among post-operative craniopharyngioma children and adolescents with that among healthy controls and to reveal the effects of rhGH replacement. Methods: Data of 79 post-operative craniopharyngioma children and adolescents in our center were retrospectively collected. Sixty patients underwent rhGH replacement during the follow-ups. We selected 36 patients who received rhGH replacement therapy, while 20 patients received rhGH replacement for at least 1 year and had complete lipid data before and after treatment and compared them with 19 patients who did not receive rhGH replacement therapy. Results: Craniopharyngioma patients had higher total cholesterol (TC) (5.17 vs 3.77 rnmol/L), triglyceride (TG) (1.51 vs 0.73 rnmol/L), and low-density lipoprotein cholesterol (LDL-C) (3.14 vs 2.10 rnmol/L), and lower high-density lipoprotein cholesterol (HDL-C) (1.06 vs 1.39 rnmol/L) than controls (all p < 0.001). The lipid profile of obese and non-obese patients was not significantly different. After rhGH replacement, TC was 0.90 mmol/L lower (p = 0.002) and LDL-C was 0.73 mmol/L lower (p = 0.010) than baseline. Although the baseline LDL-C was higher, patients with rhGH replacement had lower LDL-C (-0.73 mmol/L adjusted for age and sex, p = 0.045) after the initiation of replacement compared with patients without rhGH replacement. Conclusion: The lipid profile of obese and non-obese children and adolescents with craniopharyngioma was unfavorable, and rhGH replacement could improve their lipid profile. Keywords: craniopharyngioma, dyslipidemias, obesity, human growth hormone, hypothalamic obesity